For the past 12 years, growth stocks have been all the rage on Wall Street -- and with good reason. Historically low lending rates and abundant access to this cheap capital have fueled hiring, innovation, and even acquisitions among fast-paced companies.

But for some growth stocks, the expected uptick in revenue is just getting started. According to consensus estimates from Wall Street, the following four hypergrowth stocks are expected to increase their sales by anywhere from 1,100% to more than 4,200% over the next three to five years.

A rising green line and ascending bar chart set atop a financial newspaper with visible stock quotes.

Image source: Getty Images.

Novavax: Implied sales growth of 1,337% by 2025

Biotech stocks are always a good bet to see their sales rocket from zero to hero with their first drug approval. Clinical-stage drug developer Novavax (NVAX 0.35%) is expected to do even more with the expected emergency-use authorization (EUA) approval of its coronavirus disease 2019 (COVID-19) vaccine, NVX-CoV2373. Per Wall Street, Novavax could see sales catapult from nearly $476 million in 2020 to roughly $6.84 billion by 2025.

To date, Novavax has run two large-scale clinical trials for its COVID-19 vaccine. In March, phase 3 trial data from the U.K. showed a vaccine efficacy (VE) of 89.7%. Data from the second phase 3 study, conducted in the U.S. and Mexico, was released in June and demonstrated a very similar VE of 90.4%. The effectiveness of Novavax's vaccine makes it very likely that it'll soon be authorized in developed markets like the U.S., U.K., and Europe, and could play a key role in emerging markets, as well. Novavax may also push vaccines with lower perceived efficacy -- Johnson & Johnson and AstraZeneca -- to the back of the line.

The only real drag for Novavax shareholders has been the company's numerous delays in filing for EUA. Initially expected to go after EUA in the U.S. in the second quarter, the company now anticipates filing the appropriate paperwork during the fourth quarter. There have also been concerns about the company's timeline to ramp up vaccine production to full capacity.

Nevertheless, these delays of a quarter or two aren't going to hamper Novavax's longer-term prospects, which appear to be buoyed by the development of disease variants. The company's ability to quickly develop a vaccine, as well as its early stage research that combines influenza and COVID-19 into a single booster shot, should keep Novavax on the map for a long time to come.

An electric vehicle plugged into an outdoor charging station.

Image source: Getty Images.

Blink Charging: Implied sales growth of 2,352% by 2025

Another growth stocks with (pun intended) supercharged sales growth potential over the next five years is Blink Charging (BLNK -1.95%). Blink provides electric-vehicle (EV) charging infrastructure, as well as owns charging station networks.

The logic behind Blink's growth is pretty easy to wrap your hands around. Last year, 1.8% of all new vehicles registered in the U.S. were EVs. But by 2025, an IHS Markit study predicts that 10% of all new vehicle registrations will be EVs.  As the electrification of America takes shape, demand for charging infrastructure is only going to tick higher. There should be plenty of room for ancillary EV players like Blink Charging to take advantage of this trend for decades to come.

Based on Wall Street's consensus estimate, Blink Charging is expected to grow its sales from a reported $6.2 million in 2020 to $152 million by mid-decade. That's a 2,352% revenue increase, for those of you keeping score at home.

However, Blink's future is far from certain. Its current market cap places it at a multiple of 9 times estimated sales for 2025, and it's not particularly close to generating a profit. The company also doesn't appear to be investing any of its cash into research and development.  With no true means to stand out, it's quite possible Blink Charging gets left in the dust by its competition.

A close-up of a flowering cannabis plant growing in an indoor commercial cultivation farm.

Image source: Getty Images.

Jushi Holdings: Implied sales growth of 1,101% by 2024

U.S. marijuana stocks are a fantastic bet to deliver triple-digit aggregate sales growth over the next three to five years as new states legalize pot and already legalized states benefit from organic growth. But you can forget about triple-digit sales growth with multistate operator Jushi Holdings (JUSHF -4.21%). According to estimates from FactSet, Jushi's projected push to $969 million in annual revenue by 2024 would mark a 1,101% increase from the $80.7 million in sales generated last year.

Operating in the highly lucrative U.S. market is bound to give Jushi a boost. We've already seen 36 states legalize cannabis in some capacity, 18 of which have passed legislation to allow for the consumption and/or retail sale of adult-use weed. If New Frontier Data's latest report on the U.S. pot industry proves accurate, legal weed sales could grow by an annualized average of 21% through 2025, ultimately hitting north of $41 billion.

Jushi is a relatively small player in the cannabis space, for the time being. It has 20 operating dispensaries, but will likely end the year closer to 30, inclusive of organic openings and acquisitions. The company's core focus is on a trio of limited-license states: Virginia, Pennsylvania, and Illinois. The former issues licenses based on jurisdiction, whereas the latter two limit the aggregate number of retail and cultivation licenses assigned. By targeting limited-license states, Jushi will be somewhat protected from competitors with deeper pockets.

Similar to Novavax, Jushi is expected to turn the corner to recurring profitability in 2022. It looks to be one of the biggest bargains in the cannabis industry.

Multiple graphics processing units used to mine cryptocurrency lined up in a row.

Image source: Getty Images.

Riot Blockchain: Implied sales growth of 4,231% by 2023

The last hypergrowth stock expected to deliver insane revenue growth in the coming years is cryptocurrency mining company Riot Blockchain (RIOT -4.41%). After reporting just $12.1 million in full-year sales in 2020, Wall Street is expecting Riot to bring in $524 million in revenue by 2023. That's a greater than 4,200% sales increase in just three years.

Cryptocurrency miners are people or companies that use high-powered computers to solve complex mathematical equations to validate groups of transactions known as a block. For doing so, crypto miners are paid a block reward. In Riot's case, its revenue is soaring because it's building up its farm to mine Bitcoin (BTC -1.00%), the world's largest digital currency by market cap. The Bitcoin block reward equates to 6.25 Bitcoin, which is worth about $287,000, as of August 15.

As of the end of July, Riot Blockchain held approximately 2,687 Bitcoin on its balance sheet (these are tokens the company has mined since inception), with plans to have 25,946 Antminers in operation by early September. The goal for Riot Blockchain is to have its full fleet of miners (81,146 Antminers) in operation by the fourth quarter of 2022. 

While the sales growth in Bitcoin mining stocks is undeniable, the risks are hard to overlook, as well. Instead of being reliant on innovation, Riot is entirely dependent on investor sentiment in Bitcoin and the price of the token. We've also witnessed three declines of at least 80% in Bitcoin over the past decade, which could potentially crush Riot Blockchain's operating model.

But the real concern is that there's no barrier to entry in the crypto mining space, and Bitcoin block rewards will halve to 3.125 tokens by 2024. This is a highly competitive space with decreasing rewards.